• PDF: Delivered by email usually within 12 to 24 UK business hours.

Omrix Biopharmaceuticals - Product Pipeline Review
Q4 2010

Omrix Biopharmaceuticals - Product Pipeline Review Q4 2010

Omrix Biopharmaceuticals - Product Pipeline Review - Q4 2010

Summary

Global Market Direct's pharmaceuticals report, "Omrix Biopharmaceuticals - Product Pipeline Review - Q4 2010" provides data on the company's research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. It also gives a complete picture of the company's future therapy areas of focus.

This report is built using data and information sourced from Global Markets Direct's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct's team of industry experts.

Scope

  • Omrix Biopharmaceuticals - company overview including business description, key employees, and other facts.
  • Review of current pipeline of Omrix Biopharmaceuticals human therapeutic division.
  • Overview of pipeline therapeutics across various therapy areas.
  • Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
  • Product profiles for late stage and clinical stage products of Omrix Biopharmaceuticals with complete description of the product's developmental history, mechanism of action, clinical trials, major milestones and others.
  • Recent updates of the Omrix Biopharmaceuticals's pipeline in the last quarter.
  • Key discontinued and dormant projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Evaluate Omrix Biopharmaceuticals's strategic position with total access to a detailed intelligence on its product pipeline.
  • Assess the growth potential of Omrix Biopharmaceuticals in its therapy areas of focus.
  • Identify new drug targets and therapeutic classes in the Omrix Biopharmaceuticals's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
  • Exploit collaboration and partnership opportunities with Omrix Biopharmaceuticals.
  • Avoid Intellectual Property Rights related issues.
  • Explore the dormant and discontinued projects of Omrix Biopharmaceuticals and identify potential opportunities in those areas.
  • Do deals with an understanding of the mergers and partnerships that have shaped the sector.
  • 1 Table of Contents
    • 1.1 List of Tables
    • 1.2 List of Figures
  • 2 Introduction
  • 3 Omrix Biopharmaceuticals Snapshot
    • 3.1 Business Description
  • 4 Omrix Biopharmaceuticals- Research and Development Overview
    • 4.1 Key Therapeutic Areas
  • 5 Omrix Biopharmaceuticals- Pipeline Review
    • 5.1 Pipeline Products by Stage of Development
    • 5.2 Pipeline Products-Monotherapy
    • 5.3 Pipeline Products-Combination Treatment Modalities
  • 6 Omrix Biopharmaceuticals Pipeline Products Glance
    • 6.1 Omrix Biopharmaceuticals Phase II Pipeline
    • 6.2 Omrix Biopharmaceuticals Phase I Pipeline
    • 6.3 Omrix Biopharmaceuticals Pre-Clinical Pipeline
  • 7 Omrix Biopharmaceuticals - Drug Profiles
    • 7.1 Product 1
    • 7.1.1 Product Description
    • 7.1.2 Mechanism of Action
    • 7.1.3 R&D Progress
  • 8 Omrix Biopharmaceuticals Pipeline Analysis
    • 8.1 Omrix Biopharmaceuticals Pipeline Products by Therapeutic Class
    • 8.2 Omrix Biopharmaceuticals Pipeline Products by Target
    • 8.3 Omrix Biopharmaceuticals Pipeline by Route of Administration
    • 8.4 Omrix Biopharmaceuticals Pipeline Products by Molecule Type
  • 9 Omrix Biopharmaceuticals- Recent Pipeline Updates
  • 10 Omrix Biopharmaceuticals- Dormant Pipeline Projects
    • 10.1 Feature on Dormant Projects
  • 11 Omrix Biopharmaceuticals- Discontinued Pipeline Products
    • 11.1 Discontinued Pipeline Product Profiles
    • 11.1.1 Product 1
  • 12 Omrix Biopharmaceuticals - Featured News
  • 13 Omrix Biopharmaceuticals Statement
    • 13.1 Omrix Biopharmaceuticals - Locations and Subsidiaries
  • 14 Appendix
    • 14.1 Global Markets Direct Research Methodology
    • 14.2 Coverage
    • 14.3 Secondary Research
    • 14.4 Primary Research
    • 14.5 Models
    • 14.6 Expert Panels
    • 14.7 Contact Us
    • 14.8 Disclaimer
  • 1.1 List of Tables
    • Table 1: Omrix Biopharmaceuticals - Key Information
    • Table 2: Omrix Biopharmaceuticals - Key Facts
    • Table 3: Omrix Biopharmaceuticals - Key Therapeutic Areas
    • Table 4: Omrix Biopharmaceuticals - Pipeline by Stage of Development, 2010
    • Table 5: Omrix Biopharmaceuticals - Monotherapy Products in Pipeline, 2010
    • Table 6: Omrix Biopharmaceuticals - Combination Treatment Modalities in Pipeline, 2010
    • Table 7: Omrix Biopharmaceuticals - Phase II Pipeline, 2010
    • Table 8: Omrix Biopharmaceuticals - Phase I Pipeline, 2010
    • Table 9: Omrix Biopharmaceuticals - Pre-Clinical Pipeline, 2010
    • Table 10: Omrix Biopharmaceuticals - Pipeline By Therapeutic Class
    • Table 11: Omrix Biopharmaceuticals - Pipeline By Target
    • Table 12: Omrix Biopharmaceuticals - Pipeline By Route of Administration
    • Table 13: Omrix Biopharmaceuticals - Pipeline By Molecule Type
    • Table 14: Omrix Biopharmaceuticals - recent Pipeline Updates
    • Table 15: Omrix Biopharmaceuticals - Dormant Pipeline Projects
  • 1.2 List of Figures
    • Figure 1: Omrix Biopharmaceuticals - Research and Development Overview
    • Figure 2: Omrix Biopharmaceuticals - Pipeline by Stage of Development, 2010
    • Figure 3: Omrix Biopharmaceuticals - Monotherapy Products in Pipeline, 2010
    • Figure 4: Omrix Biopharmaceuticals - Combination Treatment Modalities in Pipeline, 2010
    • Figure 5: Omrix Biopharmaceuticals - Pipeline By Therapeutic Class and Stage of Development
    • Figure 6: Omrix Biopharmaceuticals - Pipeline By Therapeutic Class
    • Figure 7: Omrix Biopharmaceuticals - Pipeline By Target and Stage of Development
    • Figure 8: Omrix Biopharmaceuticals - Pipeline By Target
    • Figure 9: Omrix Biopharmaceuticals - Pipeline By Route of Administration and Stage of Development
    • Figure 10: Omrix Biopharmaceuticals - Pipeline By Route of Administration
    • Figure 11: Omrix Biopharmaceuticals - Pipeline By Molecule Type and Stage of Development
    • Figure 12: Omrix Biopharmaceuticals - Pipeline By Molecule Type
+44 20 8816 8548

Ask a question about Omrix Biopharmaceuticals - Product Pipeline Review

Enter the characters you see in the picture below
Captcha